Unicycive Therapeutics, Inc. (UNCY) - 10-K Summary
Business Context and Reporting Period
Company: Unicycive Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Covered: Fiscal year ended December 31, 2025
Business Overview: Unicycive is a clinical-stage biotechnology company focused on kidney disease. Its pipeline consists of two primary candidates: oxylanthanum carbonate (OLC), a next-generation phosphate binder for hyperphosphatemia in dialysis patients, and UNI-494, a novel drug candidate for acute kidney injury (AKI). The company has generated no product revenue to date and relies on financing to fund operations.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(26.6) million | $(36.7) million |
| Operating Expenses | $(29.5) million | $(32.1) million |
| Cash and Cash Equivalents | $29.2 million | $26.1 million |
| Marketable Securities | $12.1 million | $0 |
| Accumulated Deficit | $(127.8) million | $(101.3) million |
| Warrant Liability | $16.9 million | $18.9 million |
Note: The company reported a non-cash gain of $2.0 million from the change in fair value of warrant liability in 2025, compared to a loss of $5.8 million in 2024.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 28% (from $36.7M to $26.6M), primarily driven by a $10.9M decrease in Research and Development (R&D) expenses and a favorable $7.8M swing in the fair value of warrant liability.
- R&D Expenses: Decreased by 54% to $9.1M, attributed to reduced drug development and clinical costs.
- G&A Expenses: Increased by 69% to $20.4M, driven by $2.4M in marketing expenses for the anticipated commercial launch of OLC, higher professional fees, and increased labor costs.
- Liquidity: Cash and cash equivalents increased to $29.2M, bolstered by $45.2M in net proceeds from common stock sales under an At-The-Market (ATM) facility with Guggenheim Securities.
- Capital Structure: The company completed a 1-for-10 reverse stock split in June 2025. As of March 30, 2026, there were 25,237,782 shares of common stock outstanding.
Guidance, Outlook, and Material Events
Regulatory Status (OLC)
- June 2025: Received a Complete Response Letter (CRL) from the FDA regarding a cGMP deficiency at a third-party manufacturing vendor. No clinical or safety concerns were cited.
- December 2025: Resubmitted the New Drug Application (NDA) to the FDA.
- January 2026: FDA accepted the resubmission as a Class II complete response. A new PDUFA target action date was set for June 29, 2026.
Development Status (UNI-494)
- Phase I study in healthy volunteers was completed in 2024. Following FDA feedback recommending additional studies, the company has deprioritized further development of UNI-494 to focus resources on the commercialization of OLC.
Commercial Outlook
- The company is transitioning to a commercial-stage organization, having established a sales force and commercial infrastructure for OLC.
- Reimbursement strategy targets the Transitional Drug Add-on Payment Adjustment (TDAPA) for Medicare beneficiaries, which provides separate reimbursement for two years post-approval.
Risks and Contingencies
- Legal Proceedings: A putative securities class action lawsuit (Elkhodari v. Unicycive Therapeutics, Inc.) was filed in August 2025 alleging misrepresentations regarding OLC manufacturing and approval prospects. Derivative actions were also filed. The company is unable to predict the outcome.
- Capital Needs: The company expects to incur substantial additional losses and will require further capital to fund operations and commercialization. Failure to raise capital could force delays or cessation of operations.
- Manufacturing: Reliance on third-party manufacturers (Shilpa Medicare Ltd.) poses risks; previous cGMP deficiencies caused a 12-month delay in the FDA review timeline.
Key Facts for Investor Verification
- Regulatory Timeline: Verify the status of the OLC NDA resubmission and the June 29, 2026 PDUFA date, as approval is the primary catalyst for revenue.
- Manufacturing Compliance: Confirm that the third-party vendor's cGMP deficiencies cited in the June 2025 CRL have been fully resolved to avoid further delays.
- Cash Runway: Assess the sufficiency of the $29.2M cash balance plus marketable securities against the burn rate, considering the need to fund a commercial launch.
- Legal Exposure: Monitor the progress of the securities class action and derivative lawsuits regarding the manufacturing CRL disclosure.
- Reimbursement Strategy: Evaluate the likelihood of securing TDAPA status from CMS, which is critical for the economic viability of OLC in the Medicare dialysis market.